In Stock Cell Lines
Homo sapiens (Human)
Kidney
Adherent
The PPP3CA Knockout HEK293 Cell Line is a CRISPR/Cas9-edited knockout model disabling calcineurin??s catalytic subunit, the phosphatase that mediates NFAT transcription factor activation upon calcium/calmodulin stimulation. Established in HEK293 cells, it offers a loss-of-function platform to dissect NFAT-mediated transcription and calcium-regulated networks. Key applications include NFAT luciferase reporter assays, phospho-NFAT analysis, and cyclosporine A profiling, enabling studies in cardiac hypertrophy, immune signaling, and neurodegeneration. Molecular interactions with PPP3R1, calmodulin, and NFATC1 make it a precise tool for pathway dissection.
ACAD11 Knockout Hela Polyclonal Cells
Cat. No. ARG20400
HSD17B6 Knockout HAP1 Polyclonal Cells
Cat. No. ARG22637
GYS2 Knockout Hela Polyclonal Cells
Cat. No. ARG25519
DNAJC2 Knockout SK-HEP-1 Polyclonal Cells
Cat. No. ARG39248
GALNT6 Knockout 786-O Polyclonal Cells
Cat. No. ARG5184
Rabbit Coronary Artery Smooth Muscle Cell Medium
Cat. No. ARM0684
The PPP3CA Knockout HEK293 Cell Line is a CRISPR/Cas9-mediated gene-disrupted cell model in which the PPP3CA locus has been targeted to ablate expression of the calcineurin catalytic subunit. This knockout cell line provides a clean loss-of-function system for dissecting calcium/calmodulin-dependent signaling events and NFAT transcriptional regulation. By eliminating the principal catalytic component of calcineurin, researchers can decouple downstream dephosphorylation events from endogenous pathway feedback, making it an essential tool for mechanistic studies and drug profiling.
HEK293 cells are a widely used human embryonic kidney epithelial line established by transformation with adenovirus type 5 DNA. Their robust growth, high transfection efficiency, and well-characterized signaling pathways make them a preferred host for studying diverse cellular processes, including calcium signaling, immune-related pathways, and cardiac gene programs. Although derived from kidney tissue, HEK293 cells endogenously express many components of the calcineurin?CNFAT axis, providing a relevant background for PPP3CA knockout studies.
PPP3CA encodes the catalytic subunit of calcineurin, a calcium/calmodulin-dependent serine/threonine phosphatase activated by calcium influx. Calmodulin binding triggers calcineurin activation, which in complex with its regulatory subunit PPP3R1 dephosphorylates NFAT transcription factors (NFATC1?C4), promoting their nuclear translocation and transcriptional activation of targets like IL-2. Regulatory interactions with AKAP5, CABIN1, FKBP12, and cyclophilin modulate calcineurin activity, with cyclophilin?Cdrug complexes underpinning immunosuppressant action. Calcineurin also intersects with cardiac hypertrophy and Wnt signaling, placing PPP3CA as a central calcium-response integrator.
The HEK293 background provides a versatile platform for interrogating calcineurin-dependent signaling. While these cells originate from kidney epithelia, they retain functional calcium signaling machinery and NFAT-responsive transcription, allowing robust evaluation of PPP3CA function. The knockout cell line enables direct assessment of calcineurin??s role in NFAT nuclear shuttling, reporter gene activation, and downstream gene expression without confounding pharmacological side effects. Moreover, ectopic expression of cardiac- or immune-specific components can be performed to model tissue-specific calcineurin functions, enhancing the model??s utility in cardiac hypertrophy and immunosuppressant research.
Applications include NFAT luciferase reporter assays for transcriptional output, western blotting for phospho-NFAT, and immunofluorescence for NFAT localization. The line supports calcineurin activity assays for inhibitor screening and cyclosporine A profiling, as well as calcium imaging to link calcium signals to NFAT dynamics. It is valuable for cardiac hypertrophy research, autoimmune disease modeling, and Alzheimer??s-related signaling studies. For further information, contact Ascent Research.
